(Reuters) -Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for ...

PET-CT imaging with [18 F]fluorodeoxyglucose (FDG) and [18 F]fluorocholine (FCH) altered treatment plans in only a tiny ...

Mutations in BRCA1 do not appear to contribute significantly to the risk of prostate cancer progression, according to DNA ...

If you suffered losses exceeding $100,000 in Merck between February 3, 2022 and February 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at ...

Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its blockbuster cancer drug Keytruda in certain patients with head and neck cancer.

Eli Lilly and Company, Johnson & Johnson, Pfizer, Merck & Co., Inc., and Novo Nordisk A/S are the five Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool. These ...

Merck Life Science opens formulation & technology centre in Turbhe, Navi Mumbai: Our Bureau, Bengaluru Tuesday, February 25, ...

Merck & Co. is facing a class action lawsuit over Gardasil sales projections. Learn how to recover losses with Levi & ...

The ‘London’ Bus theory goes that if one takeover emerges in a particular sector, then others will follow in quick succession ...

Ligand originated, structured, and invested $50 million and led a syndicate of co-investors who invested $25 million in ...

Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major ...

The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...